BidaskClub Upgrades BioScrip (BIOS) to “Hold”

BidaskClub upgraded shares of BioScrip (NASDAQ:BIOS) from a sell rating to a hold rating in a research report released on Friday.

A number of other equities research analysts have also recently commented on the company. SunTrust Banks reiterated a buy rating and set a $3.25 target price on shares of BioScrip in a report on Thursday, March 8th. Craig Hallum reiterated a buy rating and set a $3.50 target price on shares of BioScrip in a report on Thursday, March 8th. Finally, Zacks Investment Research cut BioScrip from a hold rating to a sell rating in a report on Tuesday, March 13th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $3.45.

NASDAQ BIOS opened at $2.43 on Friday. BioScrip has a 1-year low of $1.80 and a 1-year high of $3.39. The company has a market capitalization of $333.95 million, a P/E ratio of -5.52 and a beta of 0.08. The company has a quick ratio of 1.30, a current ratio of 1.70 and a debt-to-equity ratio of -4.79.

BioScrip (NASDAQ:BIOS) last announced its earnings results on Thursday, May 10th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The business had revenue of $168.60 million during the quarter, compared to analysts’ expectations of $164.72 million. The business’s revenue was down 22.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.18) EPS. equities research analysts expect that BioScrip will post -0.31 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the business. Wells Fargo & Company MN grew its holdings in BioScrip by 40.9% during the 3rd quarter. Wells Fargo & Company MN now owns 161,814 shares of the company’s stock valued at $445,000 after buying an additional 47,004 shares during the last quarter. Gabelli Funds LLC grew its holdings in BioScrip by 2.0% during the 4th quarter. Gabelli Funds LLC now owns 10,357,832 shares of the company’s stock valued at $30,141,000 after buying an additional 205,379 shares during the last quarter. Royce & Associates LP grew its holdings in BioScrip by 942.6% during the 4th quarter. Royce & Associates LP now owns 1,824,500 shares of the company’s stock valued at $5,309,000 after buying an additional 1,649,500 shares during the last quarter. Gotham Asset Management LLC acquired a new stake in BioScrip during the 4th quarter valued at $114,000. Finally, Two Sigma Advisers LP grew its holdings in BioScrip by 100.4% during the 4th quarter. Two Sigma Advisers LP now owns 128,245 shares of the company’s stock valued at $373,000 after buying an additional 64,238 shares during the last quarter. Hedge funds and other institutional investors own 85.46% of the company’s stock.

About BioScrip

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply